| Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig S5. e j o p
Cervino AS et al. (2023)
|
Xla WT + ssbp2 MO
NF32 (in situ hybridization)
|
|
|
|
Fig 3 EFGHIJKL
Mann N et al. (2021)
|
Xla Wt + prdm15 MO + GFP
NF35/36 (in situ hybridization)
|
|
Galloway-Mowat syndrome 1
|
|
Fig 10 B^1
Hooker LN et al. (2017)
|
Xla Wt + pitx3 MO
NF10.5 (in situ hybridization)
|
|
|
|
Sup Fig. S4 r1c1
Buisson I et al. (2015)
|
Xla Wt + pax8 MO
NF18 (in situ hybridization)
|
|
|
|
Fig. 3A a-e
Buisson I et al. (2015)
|
Xla Wt + pax8 MO
NF25 (in situ hybridization)
|
|
|
|
fig.10.c^1
Hooker L et al. (2012)
|
Xla Wt + pitx3 MO
NF19 (in situ hybridization)
|
|
|
|
|
fig.10.d^1
Hooker L et al. (2012)
|
Xla Wt + pitx3 MO
NF27 (in situ hybridization)
|
|
|
|
fig.S2.b
Rankin SA et al. (2012)
|
Xtr Wt + osr1 MO + osr2 MO
NF18-20 (in situ hybridization)
|
|
|
|
fig.3.d
Zhang X et al. (2012)
|
Xtr Wt + trabd2a MO
NF10.5-11 (in situ hybridization)
|
|
|
|
fig.7.c
Rankin SA et al. (2011)
|
Xla Wt + sia1
NF11 (in situ hybridization)
|
|
|